|
|
Post by barnstormer on Feb 25, 2020 8:23:18 GMT -5
Hope we get a breakout of Brazil revenue and some kind of a projection for those 2020 revenues. Of course Mike learned a cruel lesson about guidance/missing last year, but we need all the news we can get to get out of this share price rut.
|
|
|
|
Post by barnstormer on Feb 21, 2020 9:20:17 GMT -5
Congratulations Sports. LA as I like to call her. Over the past few years she has been an inspiration and valued resource for all of weary longs. We have developed a brother/sister style relationship meaning we may have some spirited disagreements on investing and politics, but always remain friends. I wish her a successful and satisfying career with VDEX and must say I just wish MNKD would have snatched her up a couple of years ago to run their social media campaign. We would all be better off now. You go girl!
|
|
|
|
Post by barnstormer on Feb 18, 2020 14:01:16 GMT -5
All good points above. So where is Kendall in all of this? He is Mike's Golden Boy from the ADA? Perhaps he really wasn't a player there and he doesn't seem to be one here. His impact on the veins of gold he was mining from the MNKD vaults must have experienced a cave in. Little has come out in the last two years since his boasts made at the ASM. He has few if any shares. Looks like a bust to me.
|
|
|
|
Post by barnstormer on Feb 15, 2020 23:54:25 GMT -5
I would tend to think history suggests your stated dangerous outcome is actually the most likely. I don't buy Nate's opinion that something great for share price is inevitable. Regardless, CEO replaced or no, more shares must be issued to extend the runway to cash flow b/e. That is the share price catalyst. Can the company get there before running out of money and debt is due. Personally - issuing more shares which creates no further debt is an enevitable, but inconsequential event to the big picture and to the realization of investment goal outcomes. 200 Million shares out versus 300 Million shares out (versus 400 million plus presplit) will not stop an acceptable share price target if it ultimately means a multi-Billion valuation with several growing product lines under T/S. Ah yes....more shares that will go to the short side before the ink is dried. That's why we need a partner with cash so we don't have to set up the success of more shorts. |
|
|
|
Post by barnstormer on Feb 15, 2020 10:20:14 GMT -5
A little off topic, but thought it worth mentioning. I was walking the dogs along San Diego Bay yesterday and an out of town young couple enjoying the San Diego sunshine asked if I'd take their picture. A conversation ensued and the young lady said she was attending a company meeting for Solara a diabetes medical supply company. She also mention she had worked for Novo. I asked if she had heard of Afrezza and she smiled and said "yes the inhaled insulin". She also said she thought Mannkind was a great company. Go figure.
|
|
|
|
Post by barnstormer on Feb 9, 2020 12:05:05 GMT -5
I’m of the opinion that if there is sabotage that it’s unintentional. In my opinion the business plan created by the current CEO is bad because it appears to follow the Big Pharma SOP for launching new drugs. In the right hands, Technosphere Insulin has the potential to disrupt the diabetes treatment industry and, as is the case with all disruptive technology, you must either go big or go home. MC is afraid to go big and, frankly, doesn’t possess the skill set needed for successfully introducing disruptive medical innovations. This may sound harsh but MannKind’s current CEO is not a leader. He is a follower. Well said. There are too many things Mike has done that shows his lack of CEO chutzpah. The horrible deals with BIOMM and Cipla. Lack of penetration into Canada and Mexico right accross our borders. Uneccessary dilution and the extension of low ball warrants are among the things that stand out. The rebranding launch before a website with errors and omissions is ready for prime time with important information that was on the last website is embarrasing. Wall Street sees these gaffs and moves on. A qualified CEO candidate would have known that what Afrezza/MNKD needed was not a BAU game plan used by companies with huge budgets and developed a more dynamic strategy. Mike's inability to deliver an inspiring/confident presentation at investor conferences and earnings calls is not worthy of the title and salary of CEO. Rebranding should have started with a new management team. |
|
|
|
Post by barnstormer on Feb 4, 2020 1:28:09 GMT -5
These look like shares/options to buy set aside as a compensation perk and generally have an expiration date like those lovely warrants. Compensation grants can be bought directly from the company at a discount and in this instance looks like they paid $.95. The different number of shares probably account for a vesting period. Nothing to get excited about here. What would be note worthy was if they bought a large block on the open market.
|
|
|
|
Post by barnstormer on Dec 23, 2019 9:04:30 GMT -5
How does the company benefit from this? Management Payroll Security. |
|
|
|
Post by barnstormer on Dec 23, 2019 8:30:01 GMT -5
This was not negotiated just Friday. It has been in the works and presumably when the share price was at 1.31. They are not telegraphing anything so people stop making BS up. You can post that on ST! So give us a reasonable explination if you've got one. We really don't care when it was negotiated. It should have been based on market price the day of the transaction. Anyone with savy should have made that a term of the agreement to support the extension. |
|
|
|
Post by barnstormer on Dec 23, 2019 8:25:55 GMT -5
This action to me displays Castagna's total disreagard for shareholders no matter what he says in his New York presentations. He has stated several times that MNKD is now on a strong footing, so why give CVI a discount with an extension? He obviously doesn't think the share price will be over $1.60 in June or he wouldn't have pulled this second December asault on shareholders. Let's see what lavish recognition event he spends some of this cash on to reward his team for another year of poor performance.
|
|
|
|
Post by barnstormer on Dec 23, 2019 7:14:21 GMT -5
So CVI gets to excersise at $1.30 ( 8 cents below Fri close)? What happend to the $1.60 strike? And extended the rest of the warrants to June? I was hoping I was near the end of hearing how the share price would start climbing after the warrants expired. Proceeds are $5M? So Mike let them excersise at $1.35M below the strike . Way to take care of shareholder value Mike you just gave CVI the ability to short MNKD for another 6 months with a safety valve.
|
|
|
|
Post by barnstormer on Dec 13, 2019 0:53:56 GMT -5
The prices quoted above are about $.02 per unit of Afrezza insulin, versus about $1.00 per unit of Afrezza insulin retail in the U.S. per GoodRx. If these Brazilian prices are accurate, and Mannkind is not taking a loss on selling to Brazil, then Mannkind manufacturing costs (at least marginal costs) are very, very low relative to net price. And if that is the case, why is Mannkind's gross margin so low? If the manufacturing cost per unit would drop precipitously with volume (lots of fixed cost and low marginal costs), Mannkind should cut prices and increase volume. Sales and gross margins would rise dramatically assuming that coverage by the the insurance companies and demand of uninsured diabetics is sensitive to a large reduction in price. I must be wrong somewhere above. Please advise where. Thanks. Agree. MNKD priced Afrezza too high in the U.S. Exactly Mike "We aren't at AMGEN anymore". Grab market share and then slowely increase price. BUS 101. |
|
|
|
Post by barnstormer on Dec 11, 2019 9:45:11 GMT -5
Looks like VDEX can now afford to buy their own samples! VDEX next office should open in San Paulo. Sports would love it there  |
|
|
|
Post by barnstormer on Dec 11, 2019 9:41:22 GMT -5
This doesn't sound right. In this case if I were diabetic I would just go to Brazil every 3 months to get a scrip filled all expenses paid by Afrezza savings. This could start a whole new black market for Afrezza. Oh that makes sense.....Spend $2,500 to fly to Brazil every 3 months and buy Afrezza. A 90 day Direct buy is about $900..... You do the math. Better check you airlines and discounts. You must not fly much. |
|
|
|
Post by barnstormer on Dec 11, 2019 9:09:48 GMT -5
This doesn't sound right. In this case if I were diabetic I would just go to Brazil every 3 months to get a scrip filled all expenses paid by Afrezza savings. This could start a whole new black market for Afrezza.
|
|
